Fasting and Plant-Based Diet: The participants will undergo an initial 7-day fasting regime according to Buchinger (max. 350 kcal per day as liquids), followed by a dietary intervention that encompasses a plant-based diet (PBD) and time restricted eating (TRE) for 11 weeks.
Study summary
The RiseFast pilot study will investigate the clinical, metabolic and immunological effects of fasting and plant-based diet (PBD) on patients with psoriasis (PsO) and psoriatic arthritis (PsA) on their gut microbiota. The project will combine clinical assessments, cytometric profiling, and gut microbiota analysis to explore the relationship between fasting, a plant-based diet, and psoriatic disease. The study includes a 7-day fasting period followed by 11 weeks of PBD, with the goal of improving disease activity, quality of life, and understanding the role of gut microbiota in these conditions. This approach could lead to low-cost, accessible therapeutic options with minimal side effects.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Active plaque psoriasis (PASI ≥3) or Psoriatic Arthritis fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and not meeting MDA criteria
* on stable baseline psoriatic treatment for 12 weeks before enrollment
* ≥ 18 years old
Exclusion Criteria:
* Pregnancy or breastfeeding
* underweight (BMI ≤18,5)
* eating disorder in the last 5 years
* severe internal diseases (e.g. renal insufficiency with creatinine \> 2mg/dl)
* current practice of vegan diet or fasting within the past 6 months
* use of antibiotics within the past 3 months
Primary outcome measure(s)
Psoriasis Area and Severity Index (PASI) — Date of inclusion (baseline), day 8, after 6 and 12 weeks Changes in disease activity measured by the Psoriasis Area and Severity Index (PASI) after 12 weeks compared to baseline.
Disease Activity index for PSoriatic Arthritis (DAPSA) — Date of inclusion (baseline), day 8, after 6 and 12 weeks Changes in disease activity measured by the Disease Activity index for Psoriatic Arthritis (DAPSA) after 12 weeks compared to baseline.
Trial sites (1)
Facility
City
Region
Status
Charité - Universitätsmedizin Berlin, Psoriasis-Forschungs- und BehandlungsCentrum
Berlin
State of Berlin
More Charite University, Berlin, Germany trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.